Ensign Peak Advisors
IMNM icon

Ensign Peak Advisors’s Immunome IMNM Stock Holding History

Ensign Peak Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157K Sell
7,400
-300
-4% -$6.42K ﹤0.01% 1483
2026
Q1 		$168K Hold
7,700
– – ﹤0.01% 1395
2025
Q4 		$165K Buy
+7,700
New +$135K ﹤0.01% 1399
2024
Q3 		– Sell
-113,934
Closed -$1.38M – 1712
2024
Q2 		$1.38M Buy
+113,934
New +$1.78M ﹤0.01% 1081

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Ensign Peak Advisors's IMNM Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Immunome (IMNM) stake by 3.9% in Q2 2026, selling an estimated $6.42K and leaving 7,400 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #1483.

Ensign Peak Advisors first reported a position in IMNM in Q2 2024 and has held it in 4 quarters since. The position peaked at $1.38M in Q2 2024. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Ensign Peak Advisors held 7,400 shares of Immunome worth $157K as of Q2 2026.
  • Ensign Peak Advisors sold 300 Immunome shares in Q2 2026, an estimated $6.42K.
  • Immunome made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1483 holding.
  • Ensign Peak Advisors first reported a position in Immunome in Q2 2024 and has held it in 4 quarters since.
  • Ensign Peak Advisors's Immunome position peaked at $1.38M in Q2 2024.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.